Modern Practice Podcast
Modern Practice Podcast
Vizient Medical Leadership Team
The promise and limitations of expedited approval, Part 2
12 minutes Posted Mar 16, 2023 at 2:00 pm.
] Recap of approval pathways
] Examples of accelerated approval drugs and effect of delays
] Only 50 percent of accelerated approvals converted to full approval
] Challenge in keeping track of drugs in the process
] Huge cost of ineffective drugs that win approval
] Huge cost of developing drugs that end up not working
] Need for providers to look at evidence on approved drugs
0:00
12:16
Download MP3
Show notes
On this episode of our award-winning podcast, Tom continues his discussion with two leading pharmacy experts on what medications and classes of medications are in expedited approval and what this means for patients in overall efficacy and safety, the benefits and the drawbacks.
 
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal, Clinical Operations and Quality
Vizient
 
Guests:
Jeni Hayes, PharmD, MSPharm, BCPS
Senior Clinical Manager, Pharmacy Outcomes
Center for Pharmacy Practice Excellence
Vizient
 
Steven Lucio, PharmD, BCPS
Senior Principal, Pharmacy Solutions
Center for Pharmacy Practice Excellence
Vizient
 
Show Notes:
[
[
[
[
[
[
[
 
Links | Resources:
To contact Modern Practice: [email protected]
Steven’s email: [email protected]
Jeni’s email: [email protected]
FDA’s accelerated approval update page: Click here
Vizient Pharmacy Market Highlights – Dec. 2022: PMO322_PharmacyMarketOutlook_Highlights.pdf
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Android
Google Podcasts
Spotify
Stitcher
RSS Feed